Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk to cut 1,000 jobs as diabetes competition builds

Cites intensifying US market in particular for move to reduce costs
Novo Nordisk

The world's largest insulin producer Novo Nordisk has said it will cut 1,000 jobs over the next two months in a move to reduce operating costs.

President and chief executive Rebien Sørensen said: “We deeply regret that good colleagues stand to lose their jobs, and it has been a difficult decision to make.”

The lay offs are expected to hit the firm's research and development units, its headquarters staff and its global commercial organisation.

Novo, which employs 42,300 around the world, said that 500 of the planned job losses would take place in its home of Denmark.

The reductions come after increasing pressure in the diabetes market, with downward pricing and intensifying competition for market share affecting sales - particularly within the US.

Sørensen explained that the cuts are “needed in order for us to have a sustainable balance between income and costs”.

He added: “In the current situation, we have to prioritise investments in key product launches that will bring innovation to patients and drive our future growth.”

The company said in a statement that the workforce reduction will not change its financial outlook for the year, with Novo's half-year financial statement in early August reporting building momentum for its new basal insulin product Tresiba (insulin degludec).

Sales of the drug rose 161% to $216m (DKK 1.45bn) in the first six months of 2016, but it still has some way to go to compete with the $3.1bn (€2.86bn) brought in by Sanofi's established blockbuster Lantus (insulin glargine) during the same period.

Article by
Rebecca Clifford

29th September 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...
APAC map
Pharmaceutical innovation in the APAC region
A first-of-its-kind study paints a vivid picture of the APAC region’s future...
Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...

Infographics